Table 3.
Latest investigations on polymer NPs-based therapeutic approaches for skin cancer
| Type | Chief composition | Therapeutic agent | Particle size | In vitro cytotoxicity study | Animal model | Route of administration | Ref |
|---|---|---|---|---|---|---|---|
| Polymeric micelles | D-α-tocopheryl succinates/ Chondroitin sulfate | Doxorubicin | 137.87 ± 2.32 nm | Mice melanoma cell line (B16F10) | Melanoma-bearing C57BL/6 mice | Intravenous | [281] |
| Polymeric micelles | 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[maleimide-(polyethyleneglycol)-2000] | MCP-1 peptide/ KLAKLAK peptide | 11.9 ± 2.3 nm | Mice melanoma cell line (B16F10) | Melanoma-bearing male C57BL/6 J mice | Intravenous | [282] |
| Polymeric micelles | Polyethylene glycol/ Hydroxydodecanoic acid | Doxorubicin | 200 nm | Mice melanoma cell line (B16) | - | Intravenous | [283] |
| Polymeric micelles | D-α-tocopheryl-polyethylene-glycol-succinate | All-trans-retinoic acid | 11.4 ± 0.1 nm | Human melanoma cell line (BRAFV600) | - | Topical | [284] |
| Polymeric micelles | D-α-tocopheryl polyethylene glycol 1000 succinate | Imiquimod | 13.40 ± 0.16–14.90 ± 0.13 nm | - | - | Topical | [285] |
| Dendrimers | Poly(amidoamine)/ Poly (ethylene glycol) | Cytosine-phosphate-guanine oligonucleotides/ Doxorubicin | 35 ± 4.2 nm | Mice melanoma cell line (B16F10) | Melanoma-bearing C57 mice | Intravenous | [286] |
| Dendrimers | Poly(amidoamine) | Cytosine-guanine dinucleotides | 58–68 nm | Mice melanoma cell line (B16-OVA) | Melanoma-bearing female C57BL/6 mice | Intravenous | [287] |
| Dendrimers | Poly(amidoamine)/ Iron oxide | Doxorubicin | - | Mice melanoma cell line (B16F10) | Melanoma-bearing male C57BL/6 mice | Intravenous | [288] |
| Dendrimers | Poly(amidoamine) | Celecoxib/ Fmoc-L-Leucine | - | Squamous cell carcinoma (SSC-15)/ Human normal fibroblast cell line | - | - | [289] |
| Dendrimers | Poly(amidoamine) | 5-Flurouracil | 2.45 ± 0.06–3.75 ± 0.19 nm | Human melanoma cell line (A375) | - | - | [290] |
| Polymeric nanoparticle | Poly(lactic-co-glycolic acid) | Baicalin/ Hgp peptide fragment/ CpG fragments | 123.6 nm | Mice melanoma cell line (B16F10) | Melanoma-bearing C57BL/6 mice | Intravenous | [291] |
| Polymeric nanoparticle | Poly(lactic-co-glycolic acid) | Baicalin/ Hgp peptide fragment/ CpG fragments | 168.9 nm | Mice melanoma cell line (B16F10) | Melanoma-bearing female C57BL/6 mice | Intravenous | [292] |
| Polymeric nanoparticle | Poly(lactic-co-glycolic acid)/ D-α-tocopherol polyethylene glycol 1000 succinate | Paclitaxel/ PD98059 (MAPK inhibitor) | 180 nm | Mice melanoma cell line (B16F10) | Melanoma-bearing nude mice | Intravenous | [293] |
| Polymeric nanoparticle | Bovine serum albumin | Curcumin | 150 nm | Mice melanoma cell line (B16F10) | Melanoma-bearing male C57BL/6 J mice | Intraperitoneal | [294] |
| Polymeric nanoparticle | Chitosan/ Alginate | Doxorubicin | 300 nm | Mice melanoma cell line (B16F10) | Melanoma-bearing female C57BL/6 mice | Intravenous | [295] |